User profiles for J. Maris

John M Maris

Professor Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania
Verified email at chop.edu
Cited by 54504

Recent advances in neuroblastoma

JM Maris - New England Journal of Medicine, 2010 - Mass Medical Soc
Neuroblastoma, an embryonal cancer of the autonomic nervous system, is the most
common cancer diagnosed during the first year of life. Although neuroblastoma accounts for …

Molecular biology of neuroblastoma

JM Maris, KK Matthay - Journal of clinical oncology, 1999 - ascopubs.org
PURPOSE AND RESULTS: Neuroblastoma, the most common solid extracranial neoplasm
in children, is remarkable for its clinical heterogeneity. Complex patterns of genetic …

[HTML][HTML] Malignant pheochromocytoma: current status and initiatives for future progress

…, H Lehnert, WM Manger, JM Maris… - Endocrine-related …, 2004 - erc.bioscientifica.com
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are
usually benign, but which may also present as or develop into a malignancy. Predicting such …

Identification of ALK as a major familial neuroblastoma predisposition gene

…, GP Tonini, E Rappaport, M Devoto, JM Maris - Nature, 2008 - nature.com
Neuroblastoma is a childhood cancer that can be inherited, but the genetic aetiology is largely
unknown. Here we show that germline mutations in the anaplastic lymphoma kinase (ALK…

[HTML][HTML] Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

…, SD Gillies, SL Cohn, JM Maris… - … England Journal of …, 2010 - Mass Medical Soc
Background Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal
antibody against the tumor-associated disialoganglioside GD2, has activity against …

The genetic landscape of high-risk neuroblastoma

…, J Khan, MA Marra, M Meyerson, JM Maris - Nature …, 2013 - nature.com
Neuroblastoma is a malignancy of the developing sympathetic nervous system that often
presents with widespread metastatic disease, resulting in survival rates of less than 50%. To …

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

…, JH Bushweller, FP Li, K Gardiner, M Poncz, JM Maris… - Nature …, 1999 - nature.com
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML,
MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative …

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

…, T Fry, C Mackall, Y Barash, KW Lynch, JM Maris… - Cancer discovery, 2015 - AACR
The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can
be targeted with chimeric antigen receptor–armed T cells (CART-19), but relapses with …

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium …

…, J Laliberte, D Rolland, FM Balis, JM Maris… - The lancet …, 2013 - thelancet.com
Background Various human cancers have ALK gene translocations, amplifications, or
oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic …

[PDF][PDF] Comprehensive analysis of hypermutation in human cancer

…, M Aronson, C Durno, MD Taylor, G Rechavi, JM Maris… - Cell, 2017 - cell.com
We present an extensive assessment of mutation burden through sequencing analysis of >81,000
tumors from pediatric and adult patients, including tumors with hypermutation caused …